LYNBROOK, N.Y., Jan. 22,
2018 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ:
BSTC), a biopharmaceutical company that originated and continues to
develop collagenase based-therapies with a first in class
collagenase-based product marketed as XIAFLEX® in the U.S. and
Xiapex® in Europe, today announced that BioSpecifics'
President, Tom Wegman, will present
a corporate overview at the upcoming at NobleCon14 – Noble Capital
Markets' Fourteenth Annual Investor Conference in Fort Lauderdale, Florida on Monday, January 29th at 2:00pm
E.T.
A live webcast of the presentation can be accessed under "Events
and Presentation" in the Investors section of the Company's website
at www.biospecifics.com or at
http://noble.mediasite.com/mediasite/Play/16e8db9c20ff428085bebe039f77ccdf1d.
About BioSpecifics Technologies Corp.
BioSpecifics
Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for thirteen clinical indications
to date. Injectable collagenase is marketed as XIAFLEX® in the
U.S. for the treatment of Dupuytren's contracture and Peyronie's
disease by BioSpecifics' partner, Endo International plc (Endo).
XIAFLEX® is also commercialized
in Japan, Europe, Canada and Australia for
Dupuytren's contracture and for Peyronie's disease in Europe
and Australia. The XIAFLEX research and development pipeline
includes several additional promising indications. BioSpecifics is
managing the development of XIAFLEX for uterine fibroids and is
conducting a Phase 1 clinical trial. For more information, please
visit www.biospecifics.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biospecifics-technologies-corp-to-present-at-the-noblecon14-conference-300584512.html
SOURCE BioSpecifics Technologies Corp.